Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 13/20 | 0.63 |
| ▸ | CA2 | P00918 | 13/20 | 0.63 |
| ▸ | CA12 | O43570 | 12/20 | 0.63 |
| ▸ | CA9 | Q16790 | 12/20 | 0.63 |
| ▸ | CA4 | P22748 | 6/20 | 0.55 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.50 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.50 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2280591 | 0.91 | CA1 (0.63) | CA1CA2CA12CA9CA4 | |
| SCHEMBL2422588 | 0.89 | CA12 (0.49) | CA1CA2CA12CA9CA4 | |
| SCHEMBL2283201 | 0.89 | CA1 (0.69) | CA1CA2CA12CA9CA4 | |
| SCHEMBL1164588 | 0.87 | CA12 (0.62) | CA1CA2CA12CA9CA4 | |
| SCHEMBL2276429 | 0.86 | CA1 (0.68) | CA1CA2CA12CA9CA4 | |
| SCHEMBL12317783 | 0.85 | CA1 (0.44) | CA1CA2CA12CA9CA4 | |
| SCHEMBL12920202 | 0.85 | CA12 (0.44) | CA1CA2CA12CA9 | |
| SCHEMBL2280730 | 0.84 | CA1 (0.65) | CA1CA2CA12CA9CA4 | |
| SCHEMBL2282958 | 0.84 | CA1 (0.59) | CA1CA2CA12CA9CA4 | |
| SCHEMBL12875460 | 0.84 | CA1 (0.71) | CA1CA2CA12CA9CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240133884-A1 | COMPOSITIONS AND METHODS FOR DETECTING TRYPANOSOMA CRUZI INFECTION | NATIONAL INSTITUTES OF HEALTH | 2024-04-25 | — | — | US | disclosed |
| US-11773114-B2 | Protective groups and methods for protecting benzoxaboroles or oxaboroles | SAINT JOSEPH'S UNIVERSITY (US) | 2023-10-03 | — | — | US | disclosed |
| US-20200407375-A1 | PROTECTIVE GROUPS AND METHODS FOR PROTECTING BENZOXABOROLES OR OXABOROLES | UNIVERSITY OF THE SCIENCES (US) | 2020-12-31 | — | — | US | disclosed |
| US-20190256530-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | ANACOR PHARMACEUTICALS, INC. | 2019-08-22 | — | — | US | disclosed |
| US-20190256530-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | ANACOR PHARMACEUTICALS, INC. | 2019-08-22 | — | — | US | disclosed |
| US-10301329-B2 | Boron-containing small molecules as antiprotozoal agents | ANACOR PHARMACEUTICALS, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-10301329-B2 | Boron-containing small molecules as antiprotozoal agents | ANACOR PHARMACEUTICALS, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-20160340369-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | ANACOR PHARMACEUTICALS, LLC | 2016-11-24 | — | — | US | disclosed |
| US-20160340369-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | ANACOR PHARMACEUTICALS, LLC | 2016-11-24 | — | — | US | disclosed |
| US-9493489-B2 | Boron-containing small molecules as anti-protozoal agents | ANACOR PHARMACEUTICALS, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-9440994-B2 | Boron containing small molecules as antiprotozoal agents | ANACOR PHARMACEUTICALS, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-20110207702-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTI-PROTOZOAL AGENTS | ANACOR PHARMACEUTICALS, INC. (US) | 2011-08-25 | — | — | US | disclosed |
| US-20110207702-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTI-PROTOZOAL AGENTS | ANACOR PHARMACEUTICALS, INC. (US) | 2011-08-25 | — | — | US | disclosed |
| US-20110190235-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | ANACOR PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190235-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | ANACOR PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| WO-2011019616-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | ANACOR PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | WO | disclosed |
| WO-2011019618-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | ANACOR PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | WO | disclosed |
| WO-2011019618-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | ANACOR PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | WO | disclosed |
| WO-2010045503-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTI-PROTOZOAL AGENTS | ANACOR PHARMACEUTICALS, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010045503-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTI-PROTOZOAL AGENTS | ANACOR PHARMACEUTICALS, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773114-B2 | Protective groups and methods for protecting benzoxaboroles or oxaboroles | TXN2, ABCB7, TXN | CA1 822/4885CA2 1060/4885CA12 759/4885 |
| US-20110190235-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | BTD, BAD, BRI3BP | CA1 3017/4885CA2 321/4885CA12 1698/4885 |
| US-20200407375-A1 | PROTECTIVE GROUPS AND METHODS FOR PROTECTING BENZOXABOROLES OR OXABOROLES | ABCB7, TXN2, PRDX3 | CA1 915/4885CA2 1202/4885CA12 847/4885 |
| US-20240133884-A1 | COMPOSITIONS AND METHODS FOR DETECTING TRYPANOSOMA CRUZI INFECTION | RPS27A, THEM6, CD2BP2 | CA1 2786/4885CA2 2226/4885CA12 727/4885 |
| US-20160340369-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | BTD, BAD, BRI3BP | CA1 3017/4885CA2 321/4885CA12 1698/4885 |
| US-10301329-B2 | Boron-containing small molecules as antiprotozoal agents | BTD, BAD, BRI3BP | CA1 3017/4885CA2 321/4885CA12 1698/4885 |
| US-20190256530-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | BTD, BAD, BRI3BP | CA1 3017/4885CA2 321/4885CA12 1698/4885 |
| US-20110207702-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTI-PROTOZOAL AGENTS | BRDT, BRI3BP, BTN3A1 | CA1 1800/4885CA2 194/4885CA12 945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.